

Seattle Sperm Bank



Client/Sending Facility:  
Seattle Sperm Bank

4915 25th Ave Ne Ste 204  
SEATTLE, WA 98105  
Ph: (206)588-1484  
Fax: (206) 466-4696 WAB-55

LCLS Specimen Number: 126-129-0556-0

Patient Name: 12073, DONOR

Date of Birth: [REDACTED]

Gender: M

Patient ID:

Lab Number: (J16-1786 L

Indications: DONOR

Account Number: [REDACTED]

Ordering Physician: J OLLIFFE

Specimen Type: BLOOD

Client Reference: B0040961174

Date Collected: 05/05/2016

Date Received: 05/06/2016

Date Reported: 05/21/2016

Test: Chromosome, Blood, Routine

Cells Counted: 20

Cells Analyzed: 20

Cells Karyotyped: 2

Band Resolution: 500

CYTOGENETIC RESULT: 46,XY

INTERPRETATION: NORMAL MALE KARYOTYPE

Cytogenetic analysis of PHA stimulated cultures has revealed a MALE karyotype with an apparently normal GTG banding pattern in all cells observed.

This result does not exclude the possibility of subtle rearrangements below the resolution of cytogenetics or congenital anomalies due to other etiologies.

Chromosome analysis performed by LabCorp, CLIA 45D0674994. 3701 Kirby Dr. Suite 528, Houston, TX 77098. Laboratory Director, Venkateswara R Potluri PhD.




Client/Sending Facility:  
Seattle Sperm Bank

4915 25th Ave Ne Ste 204  
SEATTLE, WA 98105  
Ph: (206)588-1484  
Fax: (206) 466-4696 WAB-55

LCLS Specimen Number: 126-129-0556-0  
Patient Name: 12073, DONOR  
Date of Birth: [REDACTED]  
Gender: M  
Patient ID:  
Lab Number: (J16-1786 L

Account Number: [REDACTED]  
Ordering Physician: J OLLIFFE  
Specimen Type: BLOOD  
Client Reference: B0040961174  
Date Collected: 05/05/2016  
Date Received: 05/06/2016





Client/Sending Facility:  
Seattle Sperm Bank

4915 25th Ave Ne Ste 204  
SEATTLE, WA 98105  
Ph: (206)588-1484  
Fax: (206) 466-4696 WAB-55

LCLS Specimen Number: 126-129-0556-0  
Patient Name: 12073, DONOR  
Date of Birth: [REDACTED]  
Gender: M  
Patient ID:  
Lab Number: (J16-1786 L

Account Number: [REDACTED]  
Ordering Physician: J OLLIFFE  
Specimen Type: BLOOD  
Client Reference: B0040961174  
Date Collected: 05/05/2016  
Date Received: 05/06/2016

Rachel Burnside, PhD, FACMG  
Board Certified Cytogeneticist

Patricia Kandalajt, MD  
Medical Director  
Peter Papenhausen, PhD  
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings,  
550 17th Ave. Suite 200, SEATTLE, WA, 98122-5789 (800) 676-8033

Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709, Medical Director, Arundhati Chatterjee, MD.  
Integrated Genetics is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.



RESULTS RECIPIENT  
**SEATTLE SPERM BANK**  
 Attn: Dr. Jeffrey Olliffe  
 4915 25th Ave NE, Suite 204W  
 Seattle, WA 98105  
 Phone: (206) 588-1484  
 Fax: (206) 588-1484  
 NPI: 1306838271  
 Report Date: 05/12/2016

MALE  
**DONOR 12073**  
 DOB: [REDACTED]  
 Ethnicity: Northern European  
 Sample Type: EDTA Blood  
 Date of Collection: 05/05/2016  
 Date Received: 05/06/2016  
 Date Tested: 05/12/2016  
 Barcode: 11004211646781  
 Indication: Egg or sperm donor

FEMALE  
 N/A

# Family Prep Screen

**NEGATIVE**

## ABOUT THIS TEST

The Counsyl Family Prep Screen (version 2.0) utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

## RESULTS SUMMARY

Risk Details	DONOR 12073	Partner
Panel Information	Family Prep Screen 2.0 Fundamental Plus Panel (21 conditions tested)	N/A
<b>All conditions tested</b> A complete list of all conditions tested can be found on page 4.	<input type="checkbox"/> <b>NEGATIVE</b> No disease-causing mutations were detected.	N/A

## CLINICAL NOTES

- None

## NEXT STEPS

- If necessary, patients can discuss residual risks with their physician or a genetic counselor.

## Methods and Limitations

**DONOR 12073** [Family Prep Screen 2.0]: sequencing, targeted genotyping, copy number analysis, and analysis of homologous regions.

### Sequencing

High-throughput sequencing is used to analyze the listed exons, as well as selected intergenic and intronic regions, of the genes in the Conditions Tested section of the report. These regions are sequenced to high coverage and the sequences are compared to standards and references of normal variation. Mutations may not be detected in areas of lower sequence coverage. On average, more than 99% of all bases in the exons listed for each gene are sequenced at the minimum read depth. Variants discovered in other exons of these genes will also be reported if they meet quality control criteria. Triplet repeats and large deletions and duplications may not be detected. Small insertions and deletions may not be as accurately determined as single nucleotide variants. Genes that have closely related pseudogenes are not well analyzed by this method.

High-throughput sequencing detects, on average, 94% of known clinically significant variants. Disease-specific detection rates and residual risks are reported as "greater than (>)" and "less than (<)" the values for targeted genotyping, respectively. More precise values are not currently available, but may become available in the future.

All variants that are a recognized cause of the disease will be reported. In addition, variants that have not previously been established as a recognized cause of disease may be identified. In these cases, only variants classified as "predicted" or "likely" pathogenic are reported. Predicted/likely pathogenic variants are described elsewhere in the report as "predicted/likely to have a negative impact on gene function". In general, predicted pathogenic variants are those which are predicted to be pathogenic based on the nature of the sequence change, while likely pathogenic variants are evaluated by reviewing reports of allele frequencies in cases and controls, functional studies, variant annotation and effect prediction, and segregation studies. Benign variants, variants of uncertain significance, and variants not directly associated with the intended disease phenotype are not reported. Literature citations validating reported variants are available upon request.

### Targeted genotyping

Targeted DNA mutation analysis is used to determine the genotypes of the listed variants in the Conditions Tested section of the report. The test is not validated for detection of homozygous mutations, and although rare, asymptomatic individuals affected by the disease may not be genotyped accurately.

### Copy number analysis

Targeted copy number analysis is used to determine the copy number of exon 7 of the *SMN1* gene relative to other genes. Other mutations may interfere with this analysis. Some individuals with two copies of *SMN1* are carriers with two *SMN1* genes on one chromosome and a *SMN1* deletion on the other chromosome. In addition, a small percentage of spinal muscular atrophy (SMA) cases are caused by nondeletion mutations in the *SMN1* gene. Thus, a test result of two *SMN1* copies significantly reduces the risk of being a carrier; however, there is still a residual risk of being a carrier and subsequently a small risk of future affected offspring for individuals with two or more *SMN1* gene copies. Some SMA cases arise as the result of *de novo* mutation events which will not be detected by carrier testing.

### Analysis of homologous regions

A combination of high-throughput sequencing, read depth-based copy number analysis, and targeted genotyping is used to determine the number of functional gene copies and/or the presence of selected loss of function mutations in certain genes that have homology to other regions. The precise breakpoints of large deletions in these regions cannot be determined, but are estimated from copy number analysis. Patients who have one or more additional copies of the *CYP21A2* gene and a loss of function mutation may not actually be a carrier of 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). In addition, some individuals with four alpha globin genes are carriers with three genes on one chromosome and a deletion on the other chromosome. This and similar carrier states, where complementary changes exist in both the gene and a pseudogene, may not be detected by the assay.



RESULTS RECIPIENT  
SEATTLE SPERM BANK  
Attn: Dr. Jeffrey Olliffe  
NPI: 1306838271  
Report Date: 05/12/2016

MALE  
DONOR 12073  
DOB: [REDACTED]  
Ethnicity: Northern European  
Barcode: 11004211646781

FEMALE  
N/A

Because the true incidence of non-classic CAH is unknown, the residual carrier and reproductive risk numbers on the report are only based on published incidences for classic CAH. However, the published prevalence of non-classic CAH is highest in individuals of Ashkenazi Jewish, Hispanic, Italian, and Yugoslav descent. Therefore, the residual and reproductive risks are likely an underestimate of overall chances for 21-hydroxylase-deficient CAH, especially in the aforementioned populations, as they do not account for non-classic CAH.

## Limitations

In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, bone marrow transplantation, blood transfusions and technical errors. If more than one variant is detected in a gene, additional studies may be necessary to determine if those variants lie on the same chromosome or different chromosomes. The Family Prep Screen does not fully address all inherited forms of intellectual disability, birth defects and genetic disease. A family history of any of these conditions may warrant additional evaluation. Furthermore, not all mutations will be identified in the genes analyzed and additional testing may be beneficial for some patients. For example, individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies, which can be identified by CBC and hemoglobin electrophoresis or HPLC (*ACOG Practice Bulletin No. 78. Obstet. Gynecol. 2007;109:229-37*), and additional Tay-Sachs disease testing can be performed using a biochemical assay (*Gross et al. Genet. Med. 2008;10(1):54-56*).

This test was developed and its performance characteristics determined by Counsyl, Inc. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation. CLIA Number: **#05D1102604**.

---

### LAB DIRECTORS

H. Peter Kang, MD, MS, FCAP

Rebecca Mar-Heyming, PhD, DABMG

## Conditions Tested

**ABCC8-related Hyperinsulinism** - Gene: ABCC8. Autosomal Recessive. Sequencing. Exons: NM\_000352:1-39. **Detection Rate:** Unknown due to rarity of disease.

**Alpha Thalassemia** - Genes: HBA1, HBA2. Autosomal Recessive. Analysis of Homologous Regions. **Variants (13):** -(alpha)20.5, --BRIT, --MEDI, --MEDII, --SEA, --THAI or --FIL, -alpha3.7, -alpha4.2, HBA1+HBA2 deletion, Hb Constant Spring, anti3.7, anti4.2, del HS-40. **Detection Rate:** Unknown due to rarity of disease.

**Bloom Syndrome** - Gene: BLM. Autosomal Recessive. Sequencing. Exons: NM\_000057:2-22. **Detection Rate:** Northern European > 10%.

**Canavan Disease** - Gene: ASPA. Autosomal Recessive. Sequencing. Exons: NM\_000049:1-6. **Detection Rate:** Northern European > 53%.

**Cystic Fibrosis** - Gene: CFTR. Autosomal Recessive. Sequencing. Exons: NM\_000492:1-27. IVS8-5T allele analysis is only reported in the presence of the R117H mutation. **Detection Rate:** Northern European > 91%.

**Familial Dysautonomia** - Gene: IKBKAP. Autosomal Recessive. Sequencing. Exons: NM\_003640:19-20,26. **Detection Rate:** Unknown due to rarity of disease.

**Fanconi Anemia Type C** - Gene: FANCC. Autosomal Recessive. Sequencing. Exons: NM\_000136:2-15. **Detection Rate:** Northern European > 54%.

**Gaucher Disease** - Gene: GBA. Autosomal Recessive. Targeted Genotyping. **Variants (10):** D409V, D448H, IVS2+1G>A, L444P, N370S, R463C, R463H, R496H, V394L, p.L29Afs\*18. **Detection Rate:** Northern European 60%.

**Glycogen Storage Disease Type Ia** - Gene: G6PC. Autosomal Recessive. Sequencing. Exons: NM\_000151:1-5. **Detection Rate:** Northern European > 61%.

**Hb Beta Chain-Related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease)** - Gene: HBB. Autosomal Recessive. Sequencing. Exons: NM\_000518:1-3. **Detection Rate:** Northern European > 83%.

**Hexosaminidase A Deficiency (Including Tay-Sachs Disease)** - Gene: HEXA. Autosomal Recessive. Sequencing. Exons: NM\_000520:1-14. **Detection Rate:** Northern European > 23%.

**Joubert Syndrome 2** - Gene: TMEM216. Autosomal Recessive. Sequencing. Exons: NM\_001173990:1-5. **Detection Rate:** Unknown due to rarity of disease.

**Lipoamide Dehydrogenase Deficiency** - Gene: DLD. Autosomal Recessive. Sequencing. Exons: NM\_000108:1-14. **Detection Rate:** Unknown due to rarity of disease.

**Maple Syrup Urine Disease Type 1B** - Gene: BCKDHB. Autosomal Recessive. Sequencing. Exons: NM\_183050:1-10. **Detection Rate:** Unknown due to rarity of disease.

**Mucopolidosis IV** - Gene: MCOLN1. Autosomal Recessive. Sequencing. Exons: NM\_020533:1-14. **Detection Rate:** Northern European > 10%.

**NEB-related Nemaline Myopathy** - Gene: NEB. Autosomal Recessive. Sequencing. Exons: NM\_004543:7-8,18,25,28,33,36,45,48,54-55,58,61,71,73-74,91,94,101,111-112,114,118-119,122-123,127,129,132-135,138,140,143,146-147. **Detection Rate:** Unknown due to rarity of disease.

**Niemann-Pick Disease, SMPD1-associated** - Gene: SMPD1. Autosomal Recessive. Sequencing. Exons: NM\_000543:1-6. **Detection Rate:** Northern European > 38%.

**Spinal Muscular Atrophy** - Gene: SMN1. Autosomal Recessive. Copy Number Analysis. **Variant (1):** SMN1 copy number. **Detection Rate:** Northern European 95%.

**Usher Syndrome Type 1F** - Gene: PCDH15. Autosomal Recessive. Sequencing. Exons: NM\_033056:2-33. **Detection Rate:** Unknown due to rarity of disease.

**Usher Syndrome Type 3** - Gene: CLRN1. Autosomal Recessive. Sequencing. Exons: NM\_174878:1-3. **Detection Rate:** Unknown due to rarity of disease.

**Walker-Warburg Syndrome** - Gene: FKTN. Autosomal Recessive. Sequencing. Exons: NM\_001079802:3-11. **Detection Rate:** Unknown due to rarity of disease.



RESULTS RECIPIENT  
**SEATTLE SPERM BANK**  
 Attn: Dr. Jeffrey Olliffe  
 NPI: 1306838271  
 Report Date: 05/12/2016

MALE  
**DONOR 12073**  
 DOB: [REDACTED]  
 Ethnicity: Northern European  
 Barcode: 11004211646781

FEMALE  
 N/A

## Risk Calculations

Below are the risk calculations for all conditions tested. Since negative results do not completely rule out the possibility of being a carrier, the **residual risk** represents the patient's post-test likelihood of being a carrier and the **reproductive risk** represents the likelihood the patient's future children could inherit each disease. These risks are inherent to all carrier screening tests, may vary by ethnicity, are predicated on a negative family history and are present even after a negative test result. Inaccurate reporting of ethnicity may cause errors in risk calculation. The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Disease	DONOR 12073 Residual Risk	Reproductive Risk
ABCC8-related Hyperinsulinism	< 1 in 110	< 1 in 50,000
Alpha Thalassemia	Alpha globin status: aa/aa.	Not calculated
Bloom Syndrome	< 1 in 500	< 1 in 1,000,000
Canavan Disease	< 1 in 500	< 1 in 1,000,000
Cystic Fibrosis	< 1 in 300	< 1 in 33,000
Familial Dysautonomia	< 1 in 500	< 1 in 1,000,000
Fanconi Anemia Type C	< 1 in 340	< 1 in 220,000
Gaucher Disease	1 in 280	1 in 120,000
Glycogen Storage Disease Type Ia	< 1 in 450	< 1 in 320,000
Hb Beta Chain-Related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease)	< 1 in 290	< 1 in 58,000
Hexosaminidase A Deficiency (Including Tay-Sachs Disease)	< 1 in 390	< 1 in 470,000
Joubert Syndrome 2	< 1 in 500	< 1 in 1,000,000
Lipoamide Dehydrogenase Deficiency	< 1 in 500	< 1 in 1,000,000
Maple Syrup Urine Disease Type 1B	< 1 in 250	< 1 in 250,000
Mucopolipidosis IV	< 1 in 500	< 1 in 1,000,000
NEB-related Nemaline Myopathy	< 1 in 500	< 1 in 1,000,000
Niemann-Pick Disease, SMPD1-associated	< 1 in 400	< 1 in 400,000
Spinal Muscular Atrophy	SMN1: 2 copies 1 in 610	1 in 84,000
Usher Syndrome Type 1F	< 1 in 190	< 1 in 150,000
Usher Syndrome Type 3	< 1 in 500	< 1 in 1,000,000
Walker-Warburg Syndrome	< 1 in 500	< 1 in 1,000,000